Business
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC
Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilo...
About this update from Lobe Sciences Ltd
[{"type":"text","content":"Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLCQuality Chemical Laboratories LLC (\"QCL\") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered into an agreement for the development of commercial formulations of L-130 for the treatment of chronic cluster headacheVancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (\"Lobe\" or the \"Company\"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced that its exclusive discovery and manufacturing partner Quality Chemical Laboratories LLC (\"QCL\") has initiated commercial formulation activities for L-130. QCL, in collaboration with Clearway Global, LLC, will prepare the chemical, manufacturing and control section of the investigational new drug application being filed later this year. Material produced at QCL will also be used in the recently announced Phase I/IIa study to evaluate L-130 as a treatment for chronic cluster headaches, a debilitating orphan disease. Mr. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, \"Our collaboration with QCL has provided Lobe access to industry leading, patent pending psilocin compounds. Lobe filed patents on the first nine of these drug candidates last July 2022. Since that time we selected L-130 and L-131 to advance into clinical development. QCL's ability to rapidly discover, validate and manufacture multiple stable psilocin compounds has put Lobe in a leadership position in the development of psychedelic derived therapies. This work has allowed Lobe to have cGMP products available for our first Phase I safety study as well as the previously announced cluster headache study.\"Dr. Yousry Sayed, Founder and CEO of QCL stated, \"We are very happy with the progress being made on this important program. Our research scientists have delivered several new stable chemical entities allowing us to use other psilocin salts instead of psilocybin as a therapeutic....